Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.39 |
| ▸ | ELANE | P08246 | 8/20 | 0.39 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4788081 | 0.90 | ELANE (0.47) | ELANEGRM1PDE10ACA2HPGDS | |
| SCHEMBL4811243 | 0.89 | KDM4E (0.39) | PDK2HSP90AA1PDK4PDK1PDK3 | |
| SCHEMBL4789485 | 0.86 | HSP90AA1 (0.36) | PDK2HSP90AA1PDK4PDK1PDK3 | |
| SCHEMBL4790262 | 0.86 | ELANE (0.46) | ELANEGRM1HPGDSROCK2GRK2 | |
| SCHEMBL4790653 | 0.77 | GRK2 (0.49) | ROCK2GRK2 | |
| SCHEMBL4788586 | 0.70 | GRM1 (0.43) | GRM1HPGDSROCK2GRK2 | |
| SCHEMBL4788086 | 0.70 | GRK2 (0.49) | ELANEROCK2GRK2 | |
| SCHEMBL4790122 | 0.70 | GRM1 (0.47) | GRM1HPGDSROCK2GRK2 | |
| SCHEMBL5109256 | 0.69 | ROCK2 (0.52) | PDK2PDK4PDK1PDK3ROCK2 | |
| SCHEMBL4788260 | 0.69 | HPGDS (0.55) | GRM1HPGDSROCK2GRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | PDK2 1263/4885HSP90AA1 849/4885PDK4 2055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.